Association of hemoglobin variability and mortality among contemporary incident hemodialysis patients.

BACKGROUND AND OBJECTIVES Evidence exists that variability in hemoglobin may be an independent risk factor for mortality among hemodialysis patients. These observations were based on a 1996 cohort, a time when anemia management differed greatly from present. Design, settings, participants and measurements: A retrospective cohort study of patients incident to Fresenius Medical Care units between 2004 and 2005 (n = 6644). Hemoglobin variability (Hgb-Var) was defined for each subject as the residual SD of a linear regression model of time on hemoglobin. RESULTS The mean (SD) of Hgb-Var was 1.13 (0.55) g/dl. In the primary analysis, each g/dl increase of Hgb-Var was associated with an adjusted hazard ratio (95% confidence interval) for all-cause mortality of 1.11 (0.92 to 1.33). No significant interaction with Hgb-Var and mortality was found on the basis of age (P = 0.22), arterial disease (P = 0.45), Hgb slope (P = 0.68), or mean Hgb (P = 0.78). When Hgb-Var was defined by a regression model that included a quadratic term for time (enabling descriptions of curvilinear hemoglobin trajectories), model fit was greatly improved (P for difference <0.001). The corresponding adjusted hazard ratio (95% confidence interval) for all-cause mortality was 1.17 (0.93 to 1.49). CONCLUSIONS Hgb-Var was not found to be associated with all-cause mortality when examined in a contemporary incident hemodialysis population. More research is needed to determine whether differences in these findings compared with prior analyses relate to temporal trends in anemia management or from differences in the relationship between Hgb-Var and outcomes among incident versus prevalent hemodialysis patients.

[1]  M. Joffe,et al.  History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[2]  R. Foley,et al.  Hemoglobin level variability: associations with mortality. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[3]  M. Joffe,et al.  Hemoglobin variability and mortality in ESRD. , 2007, Journal of the American Society of Nephrology : JASN.

[4]  Mark S Gilthorpe,et al.  Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia. , 2007, Journal of the American Society of Nephrology : JASN.

[5]  S. Fishbane,et al.  Evidence and implications of haemoglobin cycling in anaemia management. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  N. Powe,et al.  Relation between level or change of hemoglobin and generic and disease-specific quality of life measures in hemodialysis , 2007, Quality of Life Research.

[7]  P. Aljama,et al.  A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  R. Foley,et al.  Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[9]  Marcello Tonelli,et al.  Cohort studies: marching forward. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[10]  D. Spiegel,et al.  HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: Anemia Management in Chronic Kidney Disease: What Have We Learned after 17 Years? , 2006, Seminars in dialysis.

[11]  M. Joffe,et al.  Erratum: Anemia and mortality in hemodialysis patients: Accounting for morbidity and treatment variables updated over time (Kidney International (2005) 68 (2323-2330)) , 2005 .

[12]  Harold I Feldman,et al.  Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. , 2005, Kidney international.

[13]  Madhumathi Rao,et al.  Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. , 2005, Kidney international.

[14]  S. Fishbane,et al.  Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. , 2005, Kidney international.

[15]  Francesco Locatelli,et al.  Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  A. Collins,et al.  Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. , 2004, Kidney international.

[17]  S. Fishbane,et al.  Hemoglobin variability in epoetin-treated hemodialysis patients. , 2003, Kidney international.

[18]  B. Pereira,et al.  Hematocrit Level Associated Mortality in Hemodialysis Patients, by Ma JZ, Ebben J, Xia H, Collins AJ. J Am Soc Nephrol 10:610–619, 1999 , 2000, Seminars in dialysis.

[19]  F. Valderrábano,et al.  Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. , 2000, Journal of the American Society of Nephrology : JASN.

[20]  M. McKenna,et al.  Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  A. Collins,et al.  Hematocrit level and associated mortality in hemodialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.